Brief Title
Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy
Official Title
Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy
Brief Summary
The Senhance™ surgical robotic system, previously known as Telelap Alf-X (TransEnterix, Morrisville, NC, USA) has recently become available in the UK. It aims to provide the robotic benefits of greater accuracy, dexterity and control with similar operational costs to traditional laparoscopy. Patients randomly received either a standard laparoscopic cholecystectomy or the Senhance assisted cholecystectomy based on scheduled surgery date. A prospectively maintained database of the first 20 patients undergoing cholecystectomy with the Senhance Surgical System was retrospectively interrogated and compared to a concurrently treated group of 20 laparoscopically treated patients during the same timeframe.
Study Type
Interventional
Primary Outcome
Operative Time
Secondary Outcome
Morbidity Data
Condition
Biliary Colic
Intervention
Senhance Assisted Cholecystectomy
Study Arms / Comparison Groups
Senhance Cholecystectomy
Description: Cholecystectomy operation performed using Senhance robotic system
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
40
Start Date
February 10, 2017
Completion Date
January 1, 2018
Primary Completion Date
December 1, 2017
Eligibility Criteria
Inclusion Criteria: ASA I or II Confirmed diagnosis of biliary colic or cholecystitis Normal LFTs Exclusion Criteria: Patients unable tor unwilling to consent BMI >40
Gender
All
Ages
18 Years - 80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Sanjay Purkayastha, MD, ,
Location Countries
United Kingdom
Location Countries
United Kingdom
Administrative Informations
NCT ID
NCT03380572
Organization ID
SenhanceChole
Responsible Party
Principal Investigator
Study Sponsor
Imperial College London
Study Sponsor
Sanjay Purkayastha, MD, Principal Investigator, Imperial College London
Verification Date
May 2019